AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 9, 2026 Compass Therapeutics reported a third quarter 2026 net loss of $27.2 million, or $0.15 per common share, with $163 million in cash and marketable securities. AI-generated summary · Source: company release
Nasdaq: $CMPXTovecimig / COMPANION-002Additional survival evidenceClinical and financing risk

CMPX Stock Hub: Compass Therapeutics News, Tovecimig and FDA Evidence

Tovecimig’s response and progression results do not resolve the survival-evidence requirement. The October 24 publication and ESMO presentation preserved the non-significant randomized overall-survival result. No new BLA date was announced; on November 9 Compass said it is preparing a BLA submission and does not believe a new trial is warranted before filing, and reported $163 million of cash and marketable securities at September 30, expected to fund operations into 2028. The November 9 regular-session close was $0.8369, up 10.29% from $0.7588 on November 6.

Last updated: November 9, 2026Market reference: November 9, 2026 regular-session closeFinancial period: September 30, 2026Research edition: November 9, 2026
Full research report · PDF
Compass Therapeutics ($CMPX), research updated November 9, 2026
17 pages covering COMPANION-002 endpoints, the survival-evidence gap and FDA feedback, the early pipeline programs and the third-quarter 2026 accounts: $163.1 million of cash and marketable securities at September 30, nine-month operating cash use and the November 5 share count, plus the November 9, 2026 close of $0.8369 and a calculated equity value. For personal use only: redistribution prohibited.
Get the report (PDF)
Company-guided clinical windows · no exact day
Later in 2026 · CTX-10726 and CTX-8371 study updates

The November 9 release expects these early-program updates later this year. The separate tovecimig regulatory path must address the September survival-evidence request; as of November 9, 2026 Compass had announced no new trial plan and no BLA filing date. Pipeline guidance · October clinical update

The November 9 third-quarter release repeats that updates on both studies are expected later this year (third-quarter results). Investor events: Compass was scheduled to present at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 9 at 1:30 p.m. ET; the Stifel 2026 Healthcare Conference presentation is set for November 11 at 11:20 a.m. ET, with webcasts archived on the company’s events page (company announcement). A presentation or publication is not evidence that the FDA has accepted an alternative evidence package. Tovecimig remains investigational.
Compass Therapeutics CMPX daily stock chart
Daily chart $CMPX. The chart link is an affiliate link. Interactive chart with bull and bear scenarios on JC Just Charts →

November 6, 2026: CTX-10726 SITC data reveal VEGF-A-dependent PD-1 receptor cleavage

New mechanistic preclinical findings, not human efficacy results. Compass Therapeutics disclosed a previously unreported proposed mechanism for its investigational PD-1 x VEGF-A bispecific antibody CTX-10726 ahead of SITC poster 678 on November 7. In its laboratory experiments, multimerization of the antibody induced cleavage and removal of PD-1 from T-cell surfaces only in the presence of VEGF-A, rather than merely blocking or internalizing the receptor. This is a company-reported mechanistic observation and requires independent clinical validation.

Quantitative potency: In a human immune-cell interferon-gamma assay, adding VEGF-A reduced the EC50 from 2.0 nM to 0.2 nM, an approximately tenfold apparent increase in potency under the tested conditions. Additional in vitro and two in vivo model systems supported VEGF-A-dependent receptor cleavage. The assays are not evidence of an objective response rate, survival advantage, or superior clinical safety relative to approved checkpoint therapies.

Combination research: A surrogate of CTX-10726 combined with the company’s CD137 agonist CTX-471 inhibited tumor growth more than either agent alone in checkpoint-resistant mouse models, with increased immune-activation gene signatures. These findings remain preclinical; the combination has not demonstrated efficacy in patients.

Clinical development: A multicenter Phase 1 dose-escalation trial is enrolling patients with advanced solid tumors after checkpoint therapy, including renal-cell, gastroesophageal, hepatocellular and endometrial cancers. Its four dose levels are 0.3, 1, 3 and 10 mg/kg in a 3+3 format. The November 7 SITC poster is a mechanistic presentation, not a Phase 1 efficacy readout. Primary source: Compass Therapeutics, November 6, 2026.

Separate investment and regulatory risk: This news does not change the FDA’s earlier recommendation that Compass demonstrate overall-survival benefit before filing the tovecimig BLA for biliary tract cancer. The COMPANION-002 randomized overall-survival analysis remains non-significant and the potential tovecimig filing path is distinct from CTX-10726’s Phase 1 program.

CMPX stock at a glance

Close · November 9, 2026
$0.8369
Regular session; +10.29% versus $0.7588 on November 6. Calculated equity value about $150.7M on 180,087,915 shares (November 5, 2026).
Cash and investments · September 30
$163.1M
$41.5M cash and cash equivalents plus $121.6M marketable securities; $179.9M at June 30. Company expects funding into 2028. Source
Operating cash use · 9M 2026
$48.3M
Nine months to September 30, 2026; Q3 net loss $27.2M, or $0.15 per share. Source
COMPANION-002 response rate
18.0% vs 5.3%
Final adjudicated ORR; primary endpoint p=0.0228.
Median progression-free survival
4.7 vs 2.6 months
HR 0.44; randomized key secondary endpoint.
Randomized overall survival
Not significant
Response and PFS significance are not evidence of an overall-survival benefit.
Grade ≥3 treatment-emergent events
93.5% vs 64.2%
October 24 reported safety comparison, not treatment-related-event rates.
Crossover-adjusted OS analysis
HR 0.85; p=0.53
Post hoc exploratory two-stage estimate; 95% CI 0.59–1.26.

Where Compass Therapeutics stands now

Cash and marketable securities of $163 million at September 30, 2026 must fund a pre-commercial pipeline, while the cost and design of additional survival work remain uncertain; the company expects that balance to fund operations into 2028 under current plans. September FDA feedback recommended a study demonstrating survival benefit before the tovecimig BLA; in its November 9 results Compass said it is preparing the BLA submission, plans to engage further with the FDA and does not believe a new trial is warranted before filing. Positive ORR and PFS are separate findings, and exploratory crossover adjustments do not replace a successful randomized OS endpoint. Third-quarter results · September Form 10-Q · FDA-feedback disclosure

An endpoint hierarchy cannot be replaced by a stronger narrative. Overall survival was not statistically significant. Further trials, regulatory requirements, toxicity, recruitment and financing can extend timelines and costs. No approved treatment or definitive new BLA route is implied by publication.

The constructive case

Randomized response and PFS findings support biological activity, while September 30 resources, a company runway into 2028 and several early antibody programs provide development options if an acceptable evidence plan can be funded and executed.

The cautious case

A survival-evidence request can require substantial new work. Crossover comparisons are exploratory; the grade≥3 event burden and uncertain trial costs limit conclusions drawn from response rates alone.

Latest Compass Therapeutics news

Nov 9, 2026

Compass Therapeutics reports 2026 third quarter financial results and provides corporate update

Compass Therapeutics reported a net loss of $27.2 million, or $0.15 per common share, for the quarter ended September 30, 2026, compared to $14.3 million, or $0.08 per share, a year earlier. R&D expenses were $22.0 million, an increase of $9.2 million or 72%, primarily driven by $8.6 million of manufacturing costs related to tovecimig. Cash and marketable securities were $163 million as of September 30, 2026, with the anticipated cash runway into 2028. The company is advancing preparations for a BLA submission for tovecimig in patients with BTC and plans to further engage with the FDA.

Nov 6, 2026

Compass Therapeutics Presents Novel Mechanism of Action Data for CTX-10726 at SITC 2026

Compass Therapeutics will present data on the novel mechanism of action of CTX-10726, a PD-1 x VEGF-A bispecific antibody, at the 41st Society for Immunotherapy of Cancer (SITC) Annual Meeting. Preclinical studies showed VEGF-A-dependent cleavage of PD-1 receptors from T cells, converting PD-1 positive T cells into PD-1 negative T cells. Adding VEGF-A increased potency approximately ten-fold, reducing the EC50 from 2.0 to 0.2 nM. The presentation is poster 678 on Saturday, November 7, 2026.

Nov 2, 2026

Compass Therapeutics to participate in upcoming November investor events

Compass Therapeutics will participate in the Guggenheim 3rd Annual Healthcare Innovation Conference on Monday, November 9, 2026, and the Stifel 2026 Healthcare Conference on Wednesday, November 11, 2026. Presentations will be archived on the Company's Events page. Management will be available for one-on-one meetings during all events.

Oct 24, 2026

COMPANION-002 publication and ESMO presentation

The 168-patient trial reported ORR 18.0% versus 5.3% and PFS 4.7 versus 2.6 months. Randomized OS was not significant; the new post hoc crossover-adjusted estimate was HR 0.85, p=0.53. Publication does not replace the FDA evidence requirement.

Oct 14, 2026

Employee inducement awards announced

The company reported inducement option grants. Compensation awards create potential dilution and are not insider open-market purchases.

Sep 22, 2026

FDA recommends additional survival evidence

Compass disclosed the recommendation for a trial demonstrating survival benefit before the planned BLA. It said it would work with the agency on the path forward; no accepted alternative package was announced.

CMPX stock catalysts: early pipeline data and survival evidence

  • Later in 2026 — CTX-10726 dose-escalation update. Company window, no fixed day
  • Later in 2026 — CTX-8371 expansion-cohort update. Company window
  • No date announced — Agreement on a feasible tovecimig evidence pathway and any additional study. Regulatory and funding uncertainty
  • November 9, 2026 — Third-quarter 2026 results and Form 10-Q: $163M cash and marketable securities, runway into 2028, BLA preparation continues. Completed · company release
  • November 9, 2026 · 1:30 p.m. ET · past — Guggenheim 3rd Annual Healthcare Innovation Conference. Historical event
  • November 11, 2026 · 11:20 a.m. ET — Stifel 2026 Healthcare Conference. Investor event
  • Second half of 2027 — Initial data from the first stage of the Phase 2 study of CTX-471 in NCAM-positive Grade 3 neuroendocrine tumors and carcinomas. Company window
  • November 7, 2026 · past — SITC poster 678 on the VEGF-A-dependent PD-1 cleavage mechanism of CTX-10726; preclinical data released November 6. Historical event
  • October 24, 2026 · past — ESMO presentation and publication. Historical event

Pipeline guidance · FDA-feedback release · October 24 results

CMPX response, progression and overall survival

The primary response result and key progression endpoint were significant. The randomized overall-survival result was not. A post hoc adjustment for crossover estimates a different scenario and remains exploratory; it is not evidence of a proven survival benefit.

CMPX cash and the potential cost of additional evidence

Cash, cash equivalents and marketable securities were $163.1 million at September 30, 2026, down from $179.9 million at June 30 and $208.9 million at the end of 2025; operating activities used $48.3 million in the first nine months. Third-quarter research and development expenses rose to $22.0 million from $12.8 million a year earlier, mainly on $8.6 million of tovecimig manufacturing costs, and general and administrative expenses to $6.8 million, including $1.5 million of pre-commercialization costs; the quarterly net loss was $27.2 million. The company expects its resources to fund operations into 2028 and states that it will need additional funding to complete clinical development. Additional patients, follow-up and development programs consume resources, and an agreed trial plan is distinct from a completed financing or BLA. Third-quarter results · September Form 10-Q

Merlintrader Health Score · $CMPX

2.4out of 5
Financial resources · 30%2.5

$163.1M of cash and marketable securities at September 30, 2026, with company runway into 2028, supports development; quarterly spending rose with tovecimig manufacturing and additional survival-trial costs are uncertain.

Catalyst maturity · 30%2.5

COMPANION-002 met its response and progression-free survival endpoints, but randomized overall survival was not significant and the FDA’s September recommendation for survival evidence before a BLA remains unresolved; CTX-8371 and CTX-10726 updates are expected later in 2026.

Dilution · 20%2.5

180,087,915 common shares at November 5, 2026 plus 6.71 million pre-funded warrants; no shares were sold under the at-the-market program in the first nine months of 2026, but further clinical work and equity compensation can affect common ownership.

Trading liquidity · 10%2.0

Nasdaq Capital Market listing; the November 9, 2026 close of $0.8369 was below $1; a sustained price below $1 brings minimum-bid listing risk, and no deficiency notice had been disclosed as of November 9, 2026.

Execution · 10%2.0

Compass is preparing a BLA while disagreeing with the FDA’s recommendation for a new survival trial; the regulatory path and its cost remain unresolved.

Assessed November 9, 2026, after the third-quarter results; scores unchanged from November 6, 2026. Weighted calculation: 2.5×30% + 2.5×30% + 2.5×20% + 2.0×10% + 2.0×10% = 2.4. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.

Red flags

  • Randomized overall survival was not statistically significant.
  • Exploratory crossover adjustments do not replace the randomized endpoint.
  • The FDA evidence request can require additional time, patients and capital.
  • The company remains pre-commercial, with clinical and dilution risks.

CMPX Stock FAQ: Compass Therapeutics Questions Answered

When are Compass Therapeutics’ next CMPX clinical results expected?

Compass’s November 9, 2026 third-quarter release expects updates on the CTX-8371 expansion cohorts and on CTX-10726 dose escalation later this year, without exact days; initial data from the first stage of the CTX-471 Phase 2 are expected in the second half of 2027. Its November 2 announcement scheduled investor presentations on November 9 at 1:30 p.m. ET and November 11 at 11:20 a.m. ET; those meetings are not clinical readout dates. Third-quarter release. November 2 event schedule.

Is Compass Therapeutics’ tovecimig FDA approved, and when is its PDUFA date?

Tovecimig remained investigational in Compass’s November 9, 2026 third-quarter release, with no BLA submission date or PDUFA target announced; the company said it is preparing a BLA submission. On September 22, the company disclosed FDA feedback recommending a trial demonstrating survival benefit before BLA submission. Compass disagreed that a new trial was necessary and said it would continue engaging with the agency. October 24 regulatory status. September 22 FDA feedback and company response.

How much cash does Compass Therapeutics have?

Compass reported $163 million of cash, cash equivalents and marketable securities at September 30, 2026, down from $209 million at the end of 2025, with $48 million used in operating activities over the first nine months. In its November 9 results, after the September FDA feedback, it still expects that balance to fund operations into 2028 based on current operating plans; additional clinical work and subsequent spending can change the funding requirement. Third-quarter results. June resources, cash flows and August runway outlook. Later survival-evidence request.

How many CMPX shares are outstanding, and can Compass issue more?

Compass reported 180,087,915 common shares outstanding on November 5, 2026, unchanged from July 28; the weighted-average share count also includes pre-funded warrants for 6.7 million shares. September 10-Q. Options, employee equity awards and future financing can increase the common-share count. Continuing clinical development requires funding, and the company’s quarterly filing describes its equity compensation and capital resources. June 10-Q, cover and equity notes.

When does Compass Therapeutics report its next earnings?

Compass reported third-quarter 2026 results on November 9, 2026, together with its Form 10-Q; the date of the next financial report has not been announced. Third-quarter results. Company news archive. Latest quarterly financial release. Investor presentation schedule.

What does Compass Therapeutics do?

Compass Therapeutics develops antibody medicines for cancer. Its lead candidate, tovecimig, targets DLL4 and VEGF-A and is being studied with chemotherapy in biliary tract cancer. Other programs include CTX-8371 and CTX-10726, which target immune and blood-vessel signaling pathways. Its products remain investigational. Company and tovecimig description. Broader clinical pipeline.

Did Compass’s COMPANION-002 trial show a survival benefit?

Compass’s October 24, 2026 results reported significant response and progression-free survival findings, but no statistically significant randomized overall-survival difference. Response was 18.0% versus 5.3%, and median progression-free survival was 4.7 versus 2.6 months. The post hoc exploratory crossover-adjusted survival estimate was HR 0.85, with a 95% confidence interval of 0.59–1.26 and p=0.53; it did not establish a proven survival benefit. Published endpoint results and exploratory analysis.

What safety results did Compass report for tovecimig?

Compass’s October 24, 2026 release reported grade 3 or higher treatment-emergent adverse events in 93.5% of tovecimig-plus-paclitaxel patients versus 64.2% with paclitaxel alone. Treatment-emergent events are not automatically attributed to the drug. Overall treatment discontinuation associated with these events was 27.8% versus 11.3%. October 24 reported safety comparison.

Primary sources

Disclaimer. Published by Merlintrader for educational and informational purposes only. It is independent research, not investment, legal, tax or medical advice, not an offer or solicitation, and not a research report under applicable United States securities regulation. Nothing here is a recommendation to buy, sell or hold $CMPX or any other security.

Figures come from SEC filings, company releases and market data, with their reference dates; they can change without notice and may be outdated or incomplete when read. Verify every figure against the primary source. Clinical-stage oncology companies carry clinical, regulatory, financing and execution risks. Trial results may not support approval; company milestones may move; safety or efficacy can disappoint. Investors can lose part or all of their capital; each reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.